

=> b reg
 FILE 'REGISTRY' ENTERED AT 14:16:35 ON 31 MAR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 29 MAR 2009 HIGHEST RN 1129300-01-1
 DICTIONARY FILE UPDATES: 29 MAR 2009 HIGHEST RN 1129300-01-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l7
 L5 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
 L7 676 SEA FILE=REGISTRY SSS FUL L5

100.0% PROCESSED 6640 ITERATIONS 676 ANSWERS
 SEARCH TIME: 00.00.01

=> b hcap
 FILE 'HCAPLUS' ENTERED AT 14:16:41 ON 31 MAR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 the American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS, is
 strictly prohibited.

FILE COVERS 1907 - 31 Mar 2009 VOL 150 ISS 14
FILE LAST UPDATED: 30 Mar 2009 (20090330/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs fhitstr l11 tot

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on SIN
AN 2005:638879 HCAPLUS
DN 143:153410

TI Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases


IN Kshirsagar, Tushar A.; Griesgraber, George W.; Celebi, Abdulaziz A.; Heppner, Philip D.

PA JM Innovative Properties Company, USA
SO PCT Int. Appl., 218 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005066172	A1	20050721	2004WO-US0043474	20041222
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, DS, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU--2004312510	A1	20050721	2004AU-000312510	20041222
CA-----2552101	A1	20050721	2004CA-002552101	20041222
EP-----1699792	A1	20060913	2004EP-000815538	20041222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
CN-----1922178	A	20070228	2004CN-080042200	20041222
JP--2007530450	T	20071101	2006JP-000547424	20041222
IN-----200602371	A	20070706	2006IN-000002371	20060628
US--20070167476	A1	20070719	2007US-000596895	20070116
PRAI 2003US-00533024P	P	20031129		
2004WO-US0043474	W	20041222		
OS CASREACT 143:153410; MARPAT 143:153410				
GI				

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)
CN INDEX NAME NOT YET ASSIGNED



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I (PA, RB = independently H, halo, alk(en)yl, alkoxy, alkylthio, NH2 and derivs.; or RACCSB = (un)substituted fused hetero/aryl, fused 5- to 7-membered saturated ring; X = a bond, alkylene; Z = (un)substituted alkylene; with the proviso that the total number of C atoms contributed by X and Z = 1-3; Y = a bond, SO2, SO2-NH and derivs., CO, etc.; R = halo, OH, alk(en)yl, haloalkyl, alkoxy, alkylthio, NH2 and derivs.; R1 = H, (un)substituted alk(en)yl, hetero/aryl, etc. with proviso; and their pharmaceutically acceptable salts], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. For example, II was prepared via cyclocondensation of 1,2-diamine derivative III with chloroacetyl chloride, cyclization of imidazoquinoline, Boc-deprotection, chlorosulfonation of amine (not isolated) with MeSO2Cl, oxidation/amination with NH4OH, and TBSMS-deprotection. Certain I modulated cytokine biosynthesis by inhibiting production of interferon α and/or tumor necrosis factor TNF- α when tested in an in vitro blood cell system.

IT 1044675-88-8

RL: PAPH (Prophetic)
(Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)

RN 1044675-88-8 HCAPLUS

=> d bib abs hitrn fhitstr l11 tot

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 AN 2005:638879 HCAPLUS
 DN 143:153410
 TI Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases
 IN Kshirsagar, Tushar A.; Griesgraber, George W.; Celebi, Abdulaziz A.; Heppner, Philip D.
 PA JM Innovative Properties Company, USA
 SO PCT Int. Appl., 218 pp.
 COBEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-----2005066172	A1	20050721	2004MO-US0043474	20041222
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, EE, DE, DK, DM, ES, EC, EG, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SF, TJ, TM, TN, TR, TT, TZ, UA, US, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
NW:	BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, AY, KG, KE, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU-----200431251	A1	20050721	2004AU-00932510	20041222
CA-----2552101	A1	20050721	2004CA-009525101	20041222
EP-----1699792	A1	20060913	2004EP-000815538	20041222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IL, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AS, TR, BG, CE, EE, HU, PL, SK, BA, HR, IS, YU			
CN-----1922178	A	20070728	2004CN-080042200	20041222
JP-----200730459	T	20071101	2006JP-000547424	20041222
IN-----200602371	A	20070706	2006IN-000002371	20060628
US-----20070167476	A1	20070719	2007US-000596895	20070116
PRAI 2004MO-US0043474	P	20041222		
OS CASREACT 143:153410; MARPAT 143:153410				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I (PA, RA = independently H, halo, alk(en)yl, alkoxy, alkylthio, NH2 and derivs.; or RACNCS = (un)substituted fused hetero/aryl, fused 5- to 7-membered saturated ring; X = a bond, alkylene; Z = (un)substituted alkylene; with the proviso that the total number of C atoms contributed by X and Z = 1-3; Y = a bond, SO2, SO2-NH and derivs., CO, etc.; R = halo, OR, alk(en)yl, haloalkyl, alkoxy, alkylthio, NH2 and derivs.; R1 = H, (un)substituted alk(en)yl, hetero/aryl, etc. with proviso; and their pharmaceutically acceptable salts), were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. For example, II was prepared via cyclocondensation of 1,2-diamine derivative III with chloroacetyl chloride, cyclization of imidazoquinolinone, SOC-deprotection, chloroalkylation of amine (not isolated), with MeSO2Cl, oxidation/amination with NH4OH, and TBSMS-deprotection. Certain I modulated cytokine biosynthesis by inhibiting production of interferon α and/or tumor necrosis factor TNF- α when tested in an in vitro blood cell system.
 IT 1044675-88-B 1044675-96-B 1044675-97-F
 1044676-02-B
 RL: PRPH (Prophetic)
 (Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

860164-39-2P 860164-41-6P 860164-43-8P
 860164-45-0P 860164-47-2P 860164-49-4P
 860164-51-8P 860164-53-0P 860164-55-2P
 860164-57-4P 860164-59-6P 860164-61-0P
 860164-63-2P 860164-65-4P 860164-67-6P
 860164-69-8P 860164-71-2P 860164-73-4P
 860164-75-6P 860164-77-8P 860164-79-0P
 860164-81-4P 860164-83-6P 860164-85-8P
 860164-87-0P 860164-89-2P 860164-91-4P
 860164-93-8P 860164-95-0P 860164-97-2P
 860164-99-4P 860165-01-1P 860165-03-3P
 860165-05-5P 860165-07-7P 860165-09-9P
 860165-11-3P 860165-13-5P 860165-15-7P
 860165-16-9P 860165-18-0P 860165-20-4P
 860165-22-6P 860165-24-8P 860165-26-0P
 860165-28-2P 860165-30-4P 860165-32-6P
 860165-34-0P 860165-36-2P 860165-38-4P
 860165-40-6P 860165-42-8P 860165-44-2P
 860165-46-4P 860165-48-6P 860165-50-0P
 860165-52-2P 860165-54-4P 860165-56-6P
 860165-58-8P 860165-60-2P 860165-62-4P
 860165-64-6P 860165-66-8P 860165-68-0P
 860165-70-4P 860165-72-6P 860165-74-8P
 860165-76-0P 860165-78-2P 860165-80-6P
 860165-82-8P 860165-84-0P 860165-86-2P
 860165-88-4P 860165-90-6P 860165-92-0P
 860165-94-2P 860165-96-4P 860165-98-6P
 860166-00-3P 860166-02-5P 860166-04-7P
 860166-06-9P 860166-08-1P 860166-10-3P
 860166-12-7P 860166-14-9P 860166-16-1P
 860166-18-3P 860166-20-7P 860166-22-9P
 860166-24-1P 860166-26-3P 860166-28-5P
 860166-30-9P 860166-32-1P 860166-34-3P
 860166-36-5P 860166-38-7P 860166-40-1P
 860166-42-3P 860166-44-5P 860166-46-7P
 860166-48-9P 860166-50-3P 860166-52-5P
 860166-54-7P 860166-56-9P 860166-58-1P
 860166-60-5P 860166-62-7P 860166-64-9P
 860166-66-1P 860166-68-3P 860166-70-7P
 860166-72-9P 860166-74-1P 860166-76-3P
 860166-78-5P 860166-80-9P 860166-82-1P
 860166-84-3P 860166-86-5P 860166-88-7P
 860166-90-1P 860166-92-3P 860166-94-5P
 860166-96-7P 860166-98-9P 860167-00-0P
 860167-02-8P 860167-04-0P 860167-06-2P
 860167-08-4P 860167-10-8P 860167-12-0P
 860167-14-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

IT 860167-16-4P 860167-18-6P 860167-20-0P
 860167-22-2P 860167-24-4P 860167-26-6P
 860167-28-8P 860167-30-2P 860167-32-4P
 860167-34-6P 860167-36-8P 860167-38-0P
 860167-40-4P 860167-42-6P 860167-44-8P
 860167-46-0P 860167-48-2P 860167-50-8P
 9-(methylsulfonyl)-3-(pyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)
 IT 860170-00-9P, 6-Amino-9-(methylsulfonyl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-3-ol 860173-01-9P, (tert-butyl 11-(tert-butylidimethylsilyl)oxy)-11,12-dihydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-9(10H)-carboxylate 860173-02-0P, 11-(tert-butylidimethylsilyl)oxy-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-9(10H)-carboxylate 860173-11-1P, tert-butyl 11,12-dihydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-9(10H)-carboxylate 860173-12-2P, tert-butyl 5-oxido-11,12-dihydro-8H-

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 IT 860160-34-8P, 11-(tert-butylidimethylsilyl)oxy-9-(methylsulfonyl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine 860160-40-3P 860160-41-4P,
 9-(tert-butylidimethylsilyl)oxy-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine 860167-81-7P, 3-Bromo-9-(methylsulfonyl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine 860167-84-0P 860167-86-2P 860167-88-4P
 860167-60-8P 860167-62-0P 860167-64-2P
 860167-66-4P 860167-68-6P 860167-70-0P
 860167-72-2P 860167-74-4P 860167-76-6P
 860167-78-8P 860167-80-2P 860167-82-4P
 860167-84-6P 860167-86-8P 860168-88-0P
 860168-87-2P 860168-89-4P 860168-91-6P
 860168-93-0P 860168-95-2P 860168-97-4P
 860168-99-6P 860169-01-3P 860169-03-5P
 860169-05-7P 860169-07-9P 860169-09-1P
 860169-11-3P 860169-13-5P 860169-15-7P
 860169-17-1P 860169-19-3P 860169-21-7P
 860169-23-9P 860169-25-1P 860169-27-3P
 860169-29-5P 860169-31-7P 860169-32-0P
 860169-34-2P 860169-36-4P 860169-38-6P
 860169-40-8P 860169-42-2P 860169-44-4P
 860169-46-6P 860169-48-8P 860169-50-2P
 860169-52-4P 860169-54-6P 860169-56-8P
 860169-59-1P 860169-61-5P 860169-64-8P
 860169-67-1P 860169-69-3P 860169-71-7P
 860169-73-9P 860169-75-2P 860169-79-5P
 860169-82-0P 860169-85-3P 860169-87-5P
 860169-90-0P 860169-93-3P 860169-96-6P
 860169-98-8P 860170-01-0P 860170-04-3P
 860170-07-6P 860170-10-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RAC (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)
 IT 860160-38-6P, 6-Amino-9-(methylsulfonyl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-1-ol 860160-42-9P
 860162-53-4P 860162-55-6P 860162-57-8P
 860162-59-0P 860162-61-4P 860162-63-6P
 860162-65-8P 860162-67-0P 860162-69-2P
 860162-71-6P 860162-73-8P 860162-75-0P
 860162-77-2P 860162-79-4P 860162-81-8P
 860162-83-0P 860162-85-2P 860162-87-4P
 860162-89-6P 860162-91-0P 860162-93-2P
 860162-95-4P 860162-97-6P 860162-99-8P
 860163-01-5P 860163-03-7P 860163-05-9P
 860163-07-1P 860163-09-3P 860163-11-7P
 860163-13-9P 860163-15-1P 860163-17-3P
 860163-19-5P 860163-21-7P 860163-23-1P
 860163-25-3P 860163-27-5P 860163-29-7P
 860163-31-1P 860163-33-3P 860163-35-5P
 860163-37-7P 860163-39-9P 860163-41-3P
 860163-43-5P 860163-45-7P 860163-47-9P
 860163-49-1P 860163-51-3P 860163-53-5P
 860163-55-7P 860163-57-1P 860163-59-3P
 860163-61-7P 860163-63-9P 860163-65-1P
 860163-67-3P 860163-69-5P 860163-71-7P
 860163-73-1P 860163-75-3P 860163-77-5P
 860163-79-7P 860163-81-1P 860163-83-3P
 860163-85-5P 860163-87-7P 860163-89-9P
 860163-91-3P 860163-93-5P 860163-95-7P
 860163-97-9P 860163-99-1P 860164-01-8P
 860164-03-0P 860164-05-2P 860164-07-4P
 860164-09-6P 860164-11-0P 860164-13-2P
 860164-15-4P 860164-17-6P 860164-19-8P
 860164-21-2P 860164-23-4P 860164-25-6P
 860164-27-8P 860164-29-0P 860164-31-4P
 860164-33-6P 860164-35-8P 860164-37-0P


L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

860173-13-3P, 9,10,11,12-Tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine hydrochloride 860173-14-4P, 9,10,11,12-Tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinoline hydrochloride 860173-15-5P, 9-(Methylsulfonyl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinoline 860173-16-6P, tert-Butyl 6-amino-11-(tert-butylidimethylsilyl)oxy-11,12-dihydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-9(10H)-carboxylate 860173-17-7P, 11-(tert-butylidimethylsilyl)oxy-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine hydrochloride 860173-23-8P,
 3-Bromo-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine 860173-30-4P, tert-Butyl 3-benzyloxy-11,12-dihydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-9(10H)-carboxylate 860173-31-5P,
 3-Benzyloxy-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinoline 860173-32-6P,
 3-(Benzyloxy)-9-(methylsulfonyl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinoline 860173-35-9P,
 tert-Butyl 6-amino-3-benzyloxy-11,12-dihydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-9(10H)-carboxylate 860173-36-0P, 3-Benzyloxy-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine dihydrochloride
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; prepn. of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

IT 1045593-39-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

IT 1044675-98-B
 RL: PRPH (Prophetic)
 (Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)

RN 1044675-88-B HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED






RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr l12 tot

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:677628 HCAPLUS
 DN 145:145757
 IN Preparation of chiral fused [1,2]imidazo[4,5-c] ring compounds as inducers
 of cytokine biosynthesis for treatment of viral and neoplastic diseases
 Griesgraber, George W.; Kshirsagar, Tushar A.; Celebi, Abdulaziz A.;
 Johannessen, Sarah C.; Danielson, Michael E.; Rice, Michael J.; Wurst,
 Joshua R.
 PA JM Innovative Properties Company, USA
 SO PCT Int. Appl., 257 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO---2006074003	A2	20060713	2005WO-US0047258	20051229
WO---2006074003	A3	20071122		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
FW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SE, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TK, AP, EA, EP, OA			
AU---2005322898	A1	20060713	2005AU-000322898	20051229
CA-----2592904	A1	20060713	2005CA-002592904	20051229
EP-----1331226	A2	20070912	2005EP-000855766	20051229
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, TU			
JP---2008526754	T	20080724	2007JP-000549590	20051229
US-20080269192	A1	20081030	2007US-000813039	20070628
2004US-00640614P	P	20041230		
2003US-00697257P	P	20050707		
2005WO-US0047258	W	20051229		
OS CASREACT 145:145757; MARPAT 145:145757				
GI				



AB Title compds. I [X = a bond, straight or branched alkylene, optionally having a substituent at a C other than the C adjacent to a heteroatom; X' = straight or branched alkylene, optionally having a substituent at a C

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 other than the C adjacent to a heteroatom; provided that the sum of the ring C atoms contributed by X and X' = 1-3; Z = O, NH and derivs., N-SO2-NH- and derivs., etc.; X1 = a bond, alk(en/yn)ylene; R1 = (un)substituted alk(en/yn)yl, hetero/aryl, etc.; RA, RB = independently H, halo, alk(en)yl, alkoxyl, etc.; or when taken together RA and RB form a (un)substituted fused hetero/aryl ring, or a (un)substituted fused 5 to 7 membered satd. ring; and their pharmaceutically acceptable salts, were prepd. as immunomodulators for inducing cytokine biosynthesis in animals (no data) and in the treatment of diseases including viral and neoplastic diseases (no data). For example, II was prepd. via cyclocondensation of diamine III (prepn. given) with Et 2-chloroethanimidate-HCl, followed by TBSMS-deprotection in the presence of tetrabutylammonium fluoride/cyclization in THF, oxidn., and amination with NH4OH. Certain I modulated cytokine biosynthesis by inhibiting prodn. of interferon α and/or tumor necrosis factor TNF-α when tested in an in vitro blood cell system (no data).


IT **899818-25-2P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of chiral fused [1,2]imidazo[4,5-c] ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)

RN **899818-25-2** HCAPLUS
 CN Formic acid, compd. with 9,10,11,12-tetrahydro-12-methyl-9-(methylsulfonyl)-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine (1:?) (CA INDEX NAME)

CM 1

CRN **899818-24-1**
 CMF C16 H19 N5 O2 S




CM 2

CRN **64-18-6**
 CMF C H2 O2

O=CH-OH

IT **899818-29-6P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of chiral fused [1,2]imidazo[4,5-c] ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)
 RN **899818-29-6** HCAPLUS
 CN 10H-[1,4]Diazepino[1',2':1,2]imidazo[4,5-c]quinolin-10-one, 6-amino-8,9,11,12-tetrahydro-12-methyl- (CA INDEX NAME)

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 14:17:19 ON 31 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 14:17:19 ON 31 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:17:19 ON 31 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l13 tot
```


L13 ANSWER 1 OF 1 USPTFULL on STN
AN 2007:191295 USPTFULL
TI Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused
imidazo ring compounds
IN Kshirsagar, Tushar A., Woodbury, MN, UNITED STATES
Griesgraber, George W., Eagan, MN, UNITED STATES
Celebi, Azim A., Clark, NJ, UNITED STATES
Heppner, Phillip D., Forest Lake, MN, UNITED STATES
PI US-20070167476 Al 20070719
AI 2004US-000596895 Al 20041222 (10)
2004WO-US0043474 20041222
20070116 PCT 371 date
PRAI 2003US-000533024P 20031229 (60)
DT Utility
FS APPLICATION
LREP 3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN,
55133-3427, US
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5252
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused
imidazo ring compounds (i.e., imidazoquinolines,
tetrahydroimidazoquinolines, imidazonaphthyridines,
tetrahydroimidazonaphthyridines, and imidazopyridines), pharmaceutical
compositions containing the compounds, intermediates, methods of making,
and methods of use of these compounds as immunomodulators, for inducing
or inhibiting cytokine biosynthesis in animals and in the treatment of
diseases including viral and neoplastic diseases are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d bib abs hitstr l14 tot

L14 ANSWER 1 OF 1 USPATFULL on SIN
 AN 2008306705 USPATFULL
 TI Chiral Fused [1,2]Imidazo[4,5-c] Ring Compounds
 IN Griesgraber, George W., Eagan, MN, UNITED STATES
 Kshirsagar, Tushar A., Woodbury, MN, UNITED STATES
 Celebi, Azim A., Palo Alto, CA, UNITED STATES
 Slania, Sarah J., Eagan, MN, UNITED STATES
 Danielson, Michael E., St. Paul, MN, UNITED STATES
 Rice, Michael J., Oakdale, MN, UNITED STATES
 Wurst, Joshua R., North St. Paul, MN, UNITED STATES
 PA Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES (U.S.
 corporation)
 PI US-20080269192 A1 20081030
 AI 2005US-000813039 A1 20051229 (11)
 2005WO-US0047258 20051229
 20070628 PCT 371 date
 PRAI 2004US-000640614P 20041230 (60)
 2005US-000697257P 20050707 (60)
 DT Utility
 FS APPLICATION
 LREP WOLF GREENFIELD & SACKS, P.C., 600 ATLANTIC AVENUE, BOSTON, MA,
 02210-2206, US
 CLMN Number of claims: 37
 ECL Exemplary Claim: 1-4
 DRWN No Drawings
 LN CNT 725/
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Fused [1,2]imidazo[4,5-c] ring compounds (e.g.,
 imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines,
 imidazo[4,5-c]naphthyridines, and
 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a
 --CH(--X.sub.1--R.sub.1)--group in the fused ring at the 1-position of
 the imidazo ring, pharmaceutical compositions containing the compounds,
 intermediates, methods of making the compounds, and methods of use of
 these compounds as immunomodulators, for inducing cytokine biosynthesis
 in animals and in the treatment of diseases including viral and
 neoplastic diseases, are disclosed.
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 13:19:31 ON 31 MAR 2009)
DEL HIS Y

L1 FILE 'HCAPLUS' ENTERED AT 14:07:55 ON 31 MAR 2009
1 US20070167476/PN

FILE 'REGISTRY' ENTERED AT 14:08:25 ON 31 MAR 2009

L2 FILE 'HCAPLUS' ENTERED AT 14:08:25 ON 31 MAR 2009
TRA L1 1- RN : 1057 TERMS

L3 FILE 'REGISTRY' ENTERED AT 14:08:25 ON 31 MAR 2009
1057 SEA L2
L4 352 L3 AND NCNC2-NC5-C6-NC2NC3/ES
L5 STR
L6 37 L5
L7 676 L5 FULL
SAV TEM J895C1G1/A L7
L8 676 L7 AND NCNC2-NC5-C6-NC2NC3/ES
L9 351 L8 AND L3
L10 325 L8 NOT L9

FILE 'HCAPLUS' ENTERED AT 14:13:37 ON 31 MAR 2009

FILE 'STNGUIDE' ENTERED AT 14:13:43 ON 31 MAR 2009

L11 FILE 'HCAPLUS' ENTERED AT 14:14:07 ON 31 MAR 2009
1 L9
L12 1 L10

L13 FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 14:14:55 ON 31 MAR 2009
1 L9
L14 1 L10

FILE 'HCAPLUS' ENTERED AT 14:15:10 ON 31 MAR 2009

FILE 'STNGUIDE' ENTERED AT 14:15:28 ON 31 MAR 2009

FILE 'REGISTRY' ENTERED AT 14:16:35 ON 31 MAR 2009

FILE 'HCAPLUS' ENTERED AT 14:16:41 ON 31 MAR 2009

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 14:17:19 ON 31 MAR 2009

=>